PROFIL Institut fuer Stoffwechselforschung GmbH

The site is exploring how metabolic conditions such as obesity and diabetes influence heart health, with trials aimed at testing new medicines that could lower cardiovascular risk factors and improve vascular function.

• Impact of weight‑loss agents on blood pressure and lipid profiles
• Evaluation of renal outcomes in patients with metabolic liver disease
• Assessment of insulin‑based therapies for cardiovascular safety
• Safety and tolerability of emerging metabolic drugs in at‑risk populations

PROFIL Institut fuer Stoffwechselforschung GmbH collaborates with commercial partners to generate data that may guide future cardiovascular prevention strategies.

Research at the centre focuses on disorders of hormone regulation, chiefly type 1 and type 2 diabetes, by evaluating novel insulin formulations and agents that modulate glucose metabolism.

• Comparative studies of new insulin analogues
• Investigation of GLP‑1 receptor agonists on glycaemic control
• Pharmacodynamic profiling of combination hormone therapies
• Safety monitoring of long‑term hormonal treatment in diabetic subjects

The trials aim to improve blood‑sugar management and reduce complications associated with hormonal imbalance.

The institute conducts studies on conditions linked to nutrition and metabolism, including obesity, overweight, and non‑alcoholic steatohepatitis (NASH), seeking therapies that promote weight loss and liver health.

• Evaluation of agents that reduce liver fat content
• Weight‑management interventions combined with lifestyle counseling
• Impact of metabolic drugs on metabolic syndrome components
• Safety and efficacy of novel compounds in obese participants

Findings are intended to support new treatment options for patients struggling with excess weight and related metabolic complications.

A broad spectrum of trials investigates fundamental aspects of human metabolism, such as glucose handling, insulin sensitivity, and renal function, using both healthy volunteers and patients with metabolic disorders.

• Glucose‑tolerance assessments after novel therapeutic exposure
• Pharmacokinetic and pharmacodynamic studies of metabolic agents
• Renal function monitoring in participants with suspected metabolic liver disease
• Bioequivalence testing of insulin products in controlled settings

These investigations help clarify how new drugs influence metabolic pathways and support the development of safer, more effective treatments.